Study identification

EU PAS number

EUPAS108468

Study ID

199009

Official title and acronym

A pan-European registry-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis (Dream to TREAT AD)

DARWIN EU® study

No

Study countries

Denmark
Germany
Ireland
Netherlands
United Kingdom

Study description

This observational study will seek to characterise the profile of abrocitinib and conventional systemic treatment patients with moderate and severe atopic dermatitis in clinical practice in Europe through the involvement of 5 registries in Germany, Netherlands, UK, Ireland and Denmark. It will aim to describe the short- and long-term effectiveness of abrocitinib and conventional systemic therapies in a three-year follow-up period through the aggregated data analysis.

Study status

Finalised
Research institutions and networks

Institutions

Multiple centres: 5; Amsterdam UMC, Amsterdam, Netherlands, Bispebjerg Hospital, Copenhagen, Denmark, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, Medical School Hannover, Hannover, Germany, Technical University Dresden, Dresden, Germany, University College Dublin, Dublin, Ireland, St John's Institute of Dermatology, St Thomas' Hospital, London, UK

Networks

Contact details

Flohr Carsten

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable